Mattia D'Agostino
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab/bortezomib/lenalidomide/dexamethasone (D-VRd) remains unknown. In this study, we analyzed CTC in the phase 3 PERSEUS/EMN017 trial. TE-NDMM patients were randomized (1:1) to D-VRd with daratumumab/lenalidomide maintenance (D-VRd group) or bortezomib/lenalidomide/dexamethasone (VRd) with lenalidomide maintenance (VRd group), both with transplant. A subset of 451 of 709 patients from PERSEUS (D-VRd, 231/355; VRd, 220/354) had screening blood samples collected for CTC analysis by flow cytometry. CTC were detected in 370 patients (82%; median limit of detection, 0.0004%). CTC were prognostic of progression-free survival (PFS), independent of other factors, as a continuous (hazard ratio [HR], 1.36 [95% confidence interval (CI), 1.15-1.60]; P< .001) and categorical variable (≥0.175% CTC-high, optimal threshold). D-VRd improved PFS vs VRd in CTC-low patients (4-year rates: 88% vs 74%; HR, 0.42 [95% CI, 0.25-0.70]; P = .0013). Regardless of study treatment, minimal residual disease (MRD)-negativity rates were lower in CTC-high vs CTC-low patients (10–5: 52.2% vs 66.2%; 10–6: 34.8% vs 52.4%). D-VRd significantly increased MRD-negativity rates vs VRd among CTC-high (10–5: 69.4% vs 33.3%; 10–6: 47.2% vs 21.2%; both P< .05) and CTC-low patients (10–5: 74.4% vs 57.8%; 10–6: 65.6% vs 38.5%; both P< .001), with similar observations for sustained MRD-negativity. CTC levels are an independent prognostic factor in TE-NDMM treated with standard-of-care frontline quadruplet. D-VRd improved and sustained MRD-negativity rates in CTC-high and CTC-low, and improved PFS for CTC-low with a positive trend in CTC-high patients. This trial was registered at www.clinicaltrials.gov as #NCT03710603.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+ 1q). While many mechanisms of resistance have been associated with + 1q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of + 1q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for + 1q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of + 1q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised + 1q as a high-risk feature. There is increasing evidence that + 1q has a prognostic value and influences the duration of remission, suggesting that patients with MM and + 1q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on + 1q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of + 1q in MM.
Year:
2025
Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (31)
Roberto Piva
University of Turin
David Siegel
Chief, Myeloma Division
-
David Cairns
Professor of Clinical Trials Research
University of Leeds
Francesca Gay
Associate Professor
University of Turin
Jill Corre
-
Brian Walker
Professor
University of Miami
Vittorio Montefusco
Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
Bronno van der Holt
Erasmus University Rotterdam
Davide Crucitti
Instituto de Investigación Sanitaria de Santiago
Martin Kaiser
Professor of Haematology
The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Benedetto Bruno
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
ROBERTO MINA
Assistant professor
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Gordon Cook
University of Leeds
K. Martin Kortüm
University Hospital Würzburg
MICHELE CAVO
University of Bologna
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Robert Orlowski
Florence Maude Thomas Cancer Research Professor
The University of Texas MD Anderson Cancer Center
Eugenio Morelli
Assistant Professor
Università degli Studi di Torino
Mario Nuvolone
University of Pavia
Niccolò Bolli
Associate Professor
University of Milan
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
Evangelos Terpos
Professor of Hematology
National and Kapodistrian University of Athens - Faculty of Medicine
ELISABETTA MEREU
University of Turin
Enrique M. Ocio
Head of the Department
Marqués de Valdecilla University Hospital
Ramón García-Sanz
Profesor Titular de Medicina / Hematología
Universidad Complutense de Madrid
Albert Oriol
Institut Català d'Oncologia
Herve Avet-Loiseau
-
Bruno David Lourenço Paiva
Clinica Universidad de Navarra
Juan-José Garcés
Research Scholar
Sloan Kettering Institute
Norma C. Gutiérrez
-
Marc S. Raab
University Hospital Heidelberg
Make your next move.
Prepare your application
Review drafts before you send them.